A randomized trial of parenteral methotrexate comparing an intermediate dose with a higher dose in children with juvenile idiopathic arthritis who failed to respond to standard doses of methotrexate

Tarih
2004
Yazar
Alessio, M
Ruperto, N
Murray, KJ
Gerloni, V
Wulffraat, N
de Oliveira, SKF
Falcini, F
Dolezalova, P
Burgos-Vargas, R
Corona, F
Vesely, R
Foster, H
Davidson, J
Zulian, F
Asplin, L
Baildam, E
Consuegra, JG
Ozdogan, H
Saurenmann, R
Joos, R
Pistorio, A
Woo, P
Martini, A
Üst veri
Tüm öğe kaydını göster
Özet
Objective. To compare the safety and efficacy of parenteral methotrexate (MTX) at an intermediate dosage (15mg/m(2)/week) versus a higher dosage (30 mg/m(2)/ week) in patients with polyarticular-course juvenile idiopathic arthritis (JIA) who failed to improve while receiving standard dosages of MTX (8-12.5 mg/m(2)/ week).
Bağlantı
http://hdl.handle.net/20.500.12627/30026
https://doi.org/10.1002/art.20288
Koleksiyonlar